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Abstract 
The roles of corticotrophin-releasing factor (CRF), opioid peptides, leptin and ghrelin in 
anorexia nervosa (AN) were discussed in this paper. CRF is the key mediator of the hypo-
thalamo-pituitary-adrenal (HPA) axis and also acts at various other parts of the brain, such as 
the limbic system and the peripheral nervous system. CRF action is mediated through the 
CRF1 and CRF2 receptors, with both HPA axis-dependent and HPA axis-independent ac-
tions, where the latter shows nil involvement of the autonomic nervous system. CRF1 re-
ceptors mediate both the HPA axis-dependent and independent pathways through CRF, while 
the CRF2 receptors exclusively mediate the HPA axis-independent pathways through uro-
cortin. Opioid peptides are involved in the adaptation and regulation of energy intake and 
utilization through reward-related behavior. Opioids play a role in the addictive component of 
AN, as described by the “auto-addiction opioids theory”. Their interactions have demon-
strated the psychological aspect of AN and have shown to prevent the functioning of the 
physiological homeostasis. Important opioids involved  are β-lipotropin, β-endorphin and 
dynorphin, which interact with both µ and κ opioids receptors to regulate reward-mediated 
behavior and describe the higher incidence of AN seen in females. Moreover, ghrelin is known 
as the “hunger” hormone and helps stimulate growth hormone (GH) and hepatic insu-
lin-like-growth-factor-1(IGF-1), maintaining anabolism and preserving a lean body mass. In 
AN, high levels of GH due to GH resistance along with low levels of IGF-1 are observed. 
Leptin plays a role in suppressing appetite through the inhibition of neuropeptide Y gene. 
Moreover, the CRF, opioid, leptin and ghrelin mechanisms operate collectively at the HPA 
axis and express the physiological and psychological components of AN. Fear conditioning is 
an intricate learning process occurring at the level of the hippocampus, amygdala, lateral 
septum and the dorsal raphe by involving three distinct pathways, the HPA axis-independent 
pathway, hypercortisolemia and ghrelin. Opioids mediate CRF through noradrenergic stim-
ulation in association with the locus coeruleus. Furthermore, CRF’s inhibitory effect on 
gonadotropin releasing hormone can be further explained by the direct relationship seen 
between CRF and opioids. Low levels of gonadotropin have been demonstrated in AN where 
only estrogen has shown to mediate energy intake. In addition, estrogen is involved in reg-
ulating µ receptor concentrations, but in turn both CRF and opioids regulate estrogen. 
Moreover, opioids and leptin are both an effect of AN, while many studies have demonstrated 
a causal relationship between CRF and anorexic behavior. Moreover, leptin, estrogen and 
ghrelin play a role as predictors of survival in starvation. Since both leptin and estrogen are 
associated with higher levels of bone marrow fat they represent a longer survival than those 
who favor the ghrelin pathway. Future studies should consider cohort studies involving 
prepubertal males and females with high CRF. This would help prevent the extrapolation of 
results from studies on mice and draw more meaningful conclusions in humans. Studies should 
also consider these mechanisms in post-AN patients, as well as look into what predisposes 
certain individuals to develop AN. Finally, due to its complex pathogenesis the treatment of 
AN should focus on both the pharmacological and behavioral perspectives. 
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INTRODUCTION 
Anorexia  Nervosa  (AN)  is  an  eating  disorder 
that  continues  to  show  devastating  effects  on  both 
adolescents  and  adults,  worldwide.  The  Diagnostic 
and  Statistical  Manual  of  Mental  Disorders  has  de-
fined AN as an eating disorder in which people refuse 
to maintain a minimally required healthy weight for 
their age and height (body weight less than eighty five 
percent of expected), have an intense fear of gaining 
weight and significantly misinterpret their body and 
shape (1).  
CLASSIFICATION 
Kaye  WH  (1996)  for  academic  purposes  has 
classified patients into three different categories, low 
weight,  short-term  recovered  and  long-term  recov-
ered (2). The American Psychiatric Association (1994) 
has subdivided AN into two distinct categories. The 
first category is the restrictive type (RAN), where pa-
tients  exhibit  “restricted  food  intake  without  binge 
eating or purging,” while the second category is the 
binge-eating/purging  type  (BPAN),  involving  both 
“binge eating/purging episodes during anorexia and 
bulimia phases” (3). In addition, both categories can 
also be differentiated by their hormonal profiles, such 
that lower leptin levels have been found in RAN (4). 
On the other hand, increased impulsivity and higher 
rate of self-harm have been observed in BPAN (4-6).  
CLINICAL PRESENTATION 
There  are  repeated  acts  of  “body  checking” 
where anorexics constantly and obsessively monitor 
their  body  image  to  assure  that  they  are  thin  (7). 
Clinically, AN is differentiated on the basis of RAN 
and BPAN. In RAN, patients experience weight loss 
by  significantly  reducing  their  total  calorie  intake 
along with exaggerated physical work-outs. In BPAN, 
patients resort to vomiting and the use of laxatives or 
diuretics to stay thin (1).  
Moreover,  the  clinical  features  of  AN  can  be 
further  divided  as  mental  and  physical.  In  general, 
anorexics secretly use aberrant, unusual behavior to 
lose weight. They gradually refuse eating with family 
and out in public (1). Although, a loss of appetite is 
seen late in the course of the disorder, collecting reci-
pes and preparing fancy meals for others is evidence 
that the individual is constantly thinking of food (1). 
Moreover, carrying large amounts of candy in pock-
ets, hiding food throughout the house, disposing food 
in napkins and cutting meals into  small pieces and 
rearranging them on the plate are important details 
that give insight into the character of this disorder (1). 
In addition, compulsive stealing of candy and laxa-
tives are also seen (1). Anorexics find opportunities to 
stay  physically  active,  ranging  from  athletics  and 
dance to acts as simple as, preferring to stand rather 
than sit (7). Nevertheless, they show resistance when 
offered  help,  and  refuse  to  talk  when  confronted 
about  their  unusual  behavior  (1).  Although,  perfec-
tionists by nature, anorexics are socially-isolated in-
dividuals that also frequently suffer from depression, 
anxiety and obsessive-compulsive disorder (OCD) (1). 
Suicidal  tendencies  are  commonly  encountered  in 
patients  suffering  from  BPAN  (1).  A  mental  status 
examination reveals that the individual is alert, ori-
ented and knowledgeable on the topic of nutrition (1).  
The  profound  weight  loss  observed  in  AN  re-
sults in hypothermia (body temperature of about 35 
degrees  Celsius),  hypotension,  dependent  edema, 
bradycardia,  lanugo  and  various  metabolic  changes 
(1). Changes like amenorrhea, poor sexual adjustment 
and  epigastric  complaints  are  also  commonly  ob-
served  (1).  In  BPAN,  patients  suffer  from  hypoka-
lemic alkalosis due to self-induced vomiting and the 
abuse of purgatives (1). Moreover, an electrocardio-
gram reflects a flattening and inversion of T waves, 
depression of ST segment and lengthening of QT in-
terval in the emaciated stage (1). Rare complications 
like  gastric  dilation  and  superior  mesenteric  artery 
syndrome have also been noted (1). 
EPIDEMIOLOGY 
AN is common between the ages of ten to thirty 
years, with the greatest incidence seen at seventeen to 
eighteen  years  of  age  (1).  The  prevalence  of  AN  is 
between 0.3-0.6% (8,9) with a mortality rate of 5-18% 
per  decade,  possibly  due  to  cachexia  and  suicide 
(1,10,11). A survival analysis performed by Carter JC 
et al. (2004) demonstrated an overall relapse rate of 
35% and mean survival time of eighteen months (12). 
The high risk period for relapse was defined between 
six  to  seventeen  months  after  discharge  (12).  Key 
predictors for relapse were history of previous treat-
ment,  history  of  suicide  attempt,  associated  OCD 
symptoms at presentation, concern for body image at 
discharge and initiation of excessive physical activity 
after  discharge  (12).  Moreover,  Talbot  Y  (1983)  re-Int. J. Med. Sci. 2011, 8 
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ported a cure rate of 70% (13). Recent sources have 
suggested that 75-85% of anorexics are likely to fully 
recover (14). This estimate would increase to 90% if 
patients  undergoing  profound  recovery  were  to  be 
included (14). In addition, AN is a female dominant 
disorder. For every one to three males, nine females 
have shown to suffer from AN (8,9).  
Traditionally, AN  was a  disorder giving equal 
emphasis on the biological, psychological and socio-
logical  dysfunction.  However,  recent  evidence  has 
found  a  higher  predilection  towards  the  biological 
perspective, shifting from the bio-psycho-social mod-
el  to  the  biological  model.  Twin  studies  have  sug-
gested a moderate to high heritability (50-85%) of AN 
(15-19). In support, an adoption study performed by 
Klump  KL  et  al.  (2009)  found  similar  findings 
(59-82%) (16), while other studies also showed herita-
bility of 70% (9,20).  
Furthermore, research on AN has looked into the 
dysfunction of various neuropeptides at the level of 
the central nervous system (CNS) and the peripheral 
nervous system (PNS). Therefore, this paper will re-
view the evidence supporting the implications of cor-
ticotrophin-releasing  factor  (CRF),  opioid  peptides, 
ghrelin  and  leptin  in  the  pathogenesis  of  AN. 
Uniquely, this paper will take an integrative approach 
to bring this evidence together to propose a more ho-
listic and complete model for AN.  
STARVATION MODEL 
It  is  essential  to  understand  the  physiology  of 
starvation to better understand AN. Many effects of 
AN  are  regulated  through  the  starvation  response. 
The starvation response consists of three phases (21). 
Phase one is the period when the consumed meal has 
been  digested  and  the  body  has  entered  the 
post-absorptive phase (22). The first phase is brief and 
usually  does  not  store  any  glucose  or  glycogen  for 
energy  (22).  The  total  body  glucose  and  glycogen 
stores are four hundred eighty grams, which are usu-
ally exhausted within twenty-four hours (23). Phase 
two becomes prominent when glycogen stores com-
pletely deplete. A greater mobilization of fat is seen 
during this stage. This stage is responsible for many of 
the physiological and biochemical alterations in the 
body (22). Increase in free fatty acids (FFA) lead to an 
increase in the peroxisome proliferator-activated re-
ceptor (PPAR)-α and PPAR-  ɣ (24,25). Next, PPAR-α 
increases levels of fibroblast growth factor-21. Fibro-
blast  growth  factor-21  mediates  growth  hormone 
(GH) resistance and reduces (insulin-growth-factor-1) 
IGF-1 levels (26,27). Further, if starvation continues, 
the fat stores exhaust and the body enters phase three 
of starvation. During this phase, there is a breakdown 
of  muscle  tissue  and  the  amino  acids  liberated  are 
used in the formation of glucose for maintaining brain 
function.  This  is  called  “protein  wasting”  (21,28). 
Therefore,  adapting  to  starvation  involves  reducing 
energy  expenditure  by  suppressing  metabolic  rate, 
body temperature and delaying growth/reproduction 
(29-31). 
CRF MECHANISM  
CRF  is  a  41-amino  acid  hypothalamic  peptide 
vital  for  regulating  adrenocorticotrophic  hormone 
(ACTH)  secretion  (32-34)  and  neuroendocrine  and 
behavioral stress-related responses (35-39). Numerous 
studies  have  demonstrated  many  visceral  and  be-
havioral effects of CRF (40). CRF has shown to acti-
vate  the  hypothalamo-pituitary-adrenal  (HPA)  axis 
and other various parts of the brain, specifically, the 
limbic  system  (34,37,38,41).  Autoradiography  has 
identified  CRF  receptors  in  the  CNS  and  the  PNS 
demonstrating various physiological actions of CRF 
(40).  
Central and Peripheral Effects of CRF 
CRF  is  governed  by  two  groups  of  receptors, 
CRF1 and CRF2, belonging to the seven transmem-
brane family of receptors (42-44). The CRF1 receptors 
are found in the cerebral cortex and the anterior lobe 
of the pituitary gland mediating anxiogenic effects of 
CRF  (45-54),  while  the  CRF2  receptors  have  been 
found in the ventromedial hypothalamus (VMH) and 
the  paraventricular  nucleus  of  the  hypothalamus 
(PVNH) (34). In addition, CRF-containing cell bodies 
have been identified in the PVNH with projections to 
the median eminence (55,56). Moreover, three splice 
variants of the CRF2 receptor, α, β and ɣ, have been 
recognized (57-60). The CRF2-α receptor, abundantly 
expressed in the hypothalamus and the limbic system, 
mediates  anxiety,  depression  and  feeding  behavior 
(61),  while  CRF2-α  protein  and  mitochondrial  ribo-
nucleic acid (mRNA), densely present in the septum, 
regulates  emotional  responses  of  fear,  anxiety  and 
aggression (62,63).  
Moreover,  CRF  is  also  present  in  the  nucleus 
accumbens,  lateral  hypothalamus,  parabrachial  nu-
cleus and dorsal motor nucleus of the vagus, regulat-
ing control pathways for nutrient intake, independent 
of pituitary control (55,64,65). In addition, CRF is also 
found in those areas of the limbic system that control 
the central autonomic function (56,66-68).  
The  amygdala  is  responsible  for  causing  reac-
tions  of  arousal,  attention,  fear  and  rage  associated 
with  sympathetic  nervous  system  (SNS)  activation 
(69). Similar reactions have been observed after ad-
ministrating  CRF  intracerebroventricularly  (32). Int. J. Med. Sci. 2011, 8 
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Therefore,  the  amygdala  and  the  presence  of  CRF 
receptors are an important topic of discussion in AN. 
CRF receptors are densely located along the pathways 
to the frontal, orbital, cingulated, temporal and insu-
lar cortices (40). Moreover, the connections between 
the amygdala and the cortices are both afferent and 
efferent. Afferent connections are from the locus co-
eruleus,  hypothalamus  and  dorsomedial  thalamic 
nucleus, while the efferent connections are from the 
dorsomedial  thalamic  nucleus,  nucleus  stria  termi-
nalis,  preoptic  area,  septal  regions  and  the  arcuate 
nucleus  of  the  hypothalamus  (ARCH),  all  of  which 
contain  CRF  receptors  (40).  The  other  areas  of  the 
limbic lobe, such as, the cingulated, parahippocampal 
cortex and the hippocampus, all contain high concen-
trations of CRF receptors and are closely related to the 
hypothalamus and the neocortex (70).  
The  CRF  receptors  of  rats  and  monkeys  are 
found in the preoptic area and the ARCH, and have 
shown to regulate gonadotropin secretion (40). When 
CRF was injected into the ARCH and VMH of female 
rats, there was a decline in luteinizing hormone levels 
and  inhibition  of  sexual  behavior,  suggesting  that 
CRF  mediates  sexual  behavior  (71).  Similarly,  these 
observations were also seen in humans during condi-
tions of prolonged stress (40).  
Claes  SJ  (2004)  suggested,  “corticotrophin  re-
leasing hormone (CRH) is the most important hypo-
thalamic peptide that controls HPA axis activity” (72). 
Intracerebroventricular administration of CRF to rats, 
dogs and monkey’s activated both the HPA axis and 
the  SNS,  with  visceral,  metabolic  (32,33,73)  and  be-
havioral  changes  (32,74).  A  study  on  CRH  gene 
knockout demonstrated the impairment of the HPA 
axis function in mice (75). 
Moreover, the locus coeruleus is connected to the 
hypothalamus,  hippocampus,  cerebral  cortex,  olfac-
tory bulb, cerebellum and the spinal cord (40). Valen-
tino RJ et al. (1983) noted the activation of local neu-
rons when CRF was injected into the locus coeruleus 
of rats (76). Therefore, the locus coeruleus plays an 
“integrative role” within the CNS, endocrine system, 
autonomic system and the behavioral system due to 
its various connections and the presence of immuno-
reactive CRF and CRF receptors (40). This also sug-
gests  that  CRF  plays  the  role  of  a  common  neural 
transmission mediator (40).  
Immunoreactive  CRF  and  its  receptors  have 
been identified in peripheral tissues like the adrenal 
medulla and have shown to regulate the SNS (77-79). 
Activation of these CRF receptors affects the secretory 
activity  of  adrenal  glands  (40).  Udelsman  R  et  al. 
(1986) demonstrated that incubating CRF-containing 
cells for 24 hours resulted in dose-dependent stimu-
lation  of  epinephrine,  noradrenaline  (NA)  and 
met-enkephalin (80).  
OPIOID PEPTIDES 
Opioid peptides are responsible for adaptation 
and  regulation  of  energy  intake  and  utilization 
through reward-mediated behavior (81). They are the 
key mediators of hedonic balance and emotional re-
sponse in food choice and intake (82).The opioid pep-
tides,  β-lipotropin  (β-LP)  and  β  β-endorphin  (β-EP) 
are pro-opiomelanocortin (POMC)-derived and help 
regulate reward-mediated behavior (83,84). Another 
opioid  peptide,  dynorphin,  a  precursor  of  protein 
prodynorphin (83,84), maintains homeostasis through 
appetite control and circadian rhythms (83).  
Types of opioid peptides 
Opioid peptides are categorized as δ, µ and κ. 
These opioids occupy the  nucleus tractus solitarius, 
PVNH,  VMH,  amygdala,  the  perifornical  area,  nu-
cleus  accumbens  and  the  forebrain  regions  (85-87). 
While µ and κ opioids regulate reward-mediated be-
havior, δ opioids are involved in self-stimulation (88).  
GHRELIN 
Ghrelin is an important gastrointestinal peptide 
hormone  synthesized  and  secreted  by  the  X/A-like 
cells in the oxyntic glands of the gastric fundic mucosa 
(89) and proximal small intestine (90). Ghrelin is an 
essential “hunger” hormone secreted during starva-
tion (91). It regulates energy homeostasis by signaling 
the CNS to increase food intake and reduce energy 
expenditure  (90,91).  Ghrelin  secretion  occurs  in  a 
pulsatile manner, starting with a gradual pre-prandial 
rise,  later  peaking  at  meal  initiation  and  finally  re-
ducing to baseline levels one hour after food intake 
(92-95).  In  sum,  ghrelin  secretes  in  response  to  re-
duced gastrointestinal content and returns to baseline 
levels upon food intake (92).  
Ghrelin  appears  as  a  117-amino  acid 
pre-prohormone  which  breaks  down 
post-translational  into  a  28-amino  acid  peptide  (96) 
and  acylates  at  its  serine-3-residue  by  ghrelin 
O-acyl-transferase  (GOAT)  (97,98).  Two  forms  of 
ghrelin have been identified, the active (acyl ghrelin) 
and inactive (des-acyl ghrelin) forms (99). When acyl 
ghrelin  is  released  into  the  circulation,  it  lives  a 
half-life of thirty-minutes and subsequently converts 
into its inactive form (99). Moreover, ghrelin presents 
as an endogenous ligand for the GH secretogogue-1a 
receptor  in  the  hypothalamus  and  pituitary  gland 
(90,100,101).  
Ghrelin  plays  an  essential  role  in  feeding  be-
havior. During meal initiation,  ghrelin directly acti-Int. J. Med. Sci. 2011, 8 
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vates  the  medial  ARCH  neurons  (102). 
Ghrelin-mediated  stimulation  of  the  hypothalamic 
GH  secretogogue-1a  receptor  results  in  an  anabolic 
response. This is evident by the exaggerated release of 
orexigenic  peptides,  neuropeptide  Y  (NPY)  and 
agouti-related protein (AgRP), leading to an increase 
in  food  intake  and  decrease  in  energy  expenditure 
(103-105). 
Moreover, ghrelin stimulates the secretion of GH 
from the anterior pituitary gland with an indirect re-
lease of IGF-1 (90,106,107). Together, GH and IGF-1 
help  maintain  lean  body  mass  through  anabolism 
(108-110).  But  in  catabolic  conditions  like  AN,  GH 
encourages lipolysis and decreases glucose and pro-
tein  oxidation  in  order  to  preserve  lean  body  mass 
(109). 
Injections of exogenous ghrelin have shown to 
increase  the  adiposity  in  rodents  through  its  orexi-
genic  effect  (111-114).  Similar  findings  are  also 
demonstrated in humans through stimulation of ap-
petite  in  the  healthy  and  chronically-ill  individuals 
(107,115,116).  At  pharmacological  doses,  ghrelin  in-
creases prolactin, ACTH and cortisol secretion (106). 
Lastly, episodes of food intake directly correlate with 
the levels of endogenous ghrelin (117) in both humans 
(94) and rats (118). 
LEPTIN 
 Leptin  is  a  four-helical  structure  consisting  of 
167-amino acids. It is analogous to a cytokine and is 
also known as a “prototypical adipokine” (119,120). 
Although,  largely  produced  in  the  adipose  tissue, 
leptin is expressed in various tissues like the placenta, 
ovary,  mammary  epithelium,  bone  marrow  and 
lymphoid tissue (121,122).  
Leptin secretion follows a circadian rhythm with 
the greatest secretion seen between midnight to early 
morning  and  lowest  during  early-to-mid-afternoon 
(123-125). Leptin has shown to suppress appetite by 
inhibiting NPY gene expression at the ARCH (126). 
Moreover, leptin concentrates directly correlate with 
the amount of adiposity in an individual, generally 
low  during  starvation  and  high  in  obesity  (127). 
However, sudden changes in food intake, especially 
energy deprivation, results in wide fluctuation in the 
levels of leptin (128-130).  
Moreover, females demonstrate greater plasma 
leptin concentrates than males, but these levels sig-
nificantly  decline  after  menopause  (131).  These  dif-
ferences are largely independent of body mass index 
(BMI),  but  can  be  attributed  to  differences  in  sex 
hormones,  fat  mass  and  body  fat  distribution 
(131-133).  In  addition,  females  tend  to  accumulate 
more peripheral amounts of body fat, while men ex-
hibit an android distribution of fat. As a result, higher 
concentrates of leptin mRNA have been identified in 
the subcutaneous fat, but are scarcely present in the 
omentum (133,134). Therefore, this gives insight into 
why higher leptin levels are observed in females.  
 Leptin exerts its action through binding at the 
ObRs receptor in the CNS and at various peripheral 
tissues (135). Six isoforms of the ObRs receptor have 
been identified, ObRa, ObRb, ObRc, ObRd, ObRe and 
ObRf  (136).  Isoforms,  ObRa  and  ObRc  are  vital  in 
transporting  leptin  across  the  blood-brain  barrier 
(137,138), while ObRb is primarily involved in leptin 
signaling (136,137,139). ObRb is chiefly demonstrable 
in the hypothalamus, regulating energy homeostasis 
and neuroendocrine function (135,140). 
NEURO-PERIPHERY MECHANISMS OF 
ANOREXIA NERVOSA 
CORTICOTROPHIN-RELEASING FACTOR 
Physiological Perspective 
Existing literature has attributed AN to the dys-
function of the CRF mechanism, with increased levels 
of CRH (141). Hotta et al. (1986) demonstrated high 
levels of CRF in the cerebrospinal fluid (CSF) of ano-
rexics (308). Moreover, starvation has shown to acti-
vate the HPA axis (142-145). However, over-activity 
of the axis has been demonstrated by Carol BJ (1980) 
in depressed individuals (146). CRF receptors of the 
cerebral  cortex  and  the  limbic  system  manifest  the 
visceral  and  behavioral  components  of  depression 
(40). The clinical features attributed to CRF dysfunc-
tion and HPA-axis hyperactivity are: excessive phys-
ical  activity,  suppressed  reproductive  hormones  re-
sulting  in  decreased  sexual  behaviour  and  amenor-
rhea,  cardiovascular  changes  like  hypotension  and 
bradycardia,  anxiety,  blunted  social  interaction,  in-
creased vigilance and altered immune system func-
tion  (147-149).  CRF  has  also  shown  to  reduce  food 
intake  (39,149,150)  and  blunt  weight  gain 
(39,73,151-154), affecting both energy intake and uti-
lization. However, Krahn et al. (1990) demonstrated 
that  a  persistent  elevation  of  CRH  was  required  to 
cause an AN-like syndrome, and an intermittent ele-
vation  had  no  effect  (39).  Anorexics  possibly  differ 
from healthy individuals in being unable to adapt to 
CRH elevations (39).  
Smagin GN et al. (1998) found that CRF2 and not 
CRF1 antisense administration attenuated the effect of 
CRF  on  appetite  (155).  Urocortin  (UCN),  a 
CRH-related neuropeptide, demonstrates 20-40 times 
higher  natural  affinity  to  CRF2  receptors  than  CRF 
itself, resulting in suppression of appetite, independ-Int. J. Med. Sci. 2011, 8 
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ent  of  the  HPA-axis  and  glucocorticoid  release 
(156,157). Therefore, when dissociated from the pitu-
itary, agonists to the CRF2 receptors have shown to 
suppress appetite, while the antagonists have shown 
to enhance appetite. 
Cullen MJ et al. (2001) studied the effects of an-
tisauvignine-30  (ASV-30),  a  CRF2-selective  antago-
nist, on energy balance through the central infusion of 
CRF and UCN (44). Consequently, central infusion of 
CRF resulted in a negative energy balance attributed 
to decreased food intake and increased SNS activity. 
However,  UCN  only  showed  a  minimum  effect  ac-
counted by reduced food intake and nil involvement 
of the SNS. On the other hand, ASV-30 reversed the 
effects of both CRF and UCN by increasing food in-
take. However, ASV-30 failed to alter the effects  of 
CRF  on  the  HPA-axis  variables  like  levels  of  corti-
costerone, increased adrenal weight, reduced thymus 
and splenic weight. Also, ASV-30 had a selective af-
fect on CRF2 receptors, but demonstrated  no  meta-
bolic effects of CRF (44). Moreover, Bornstein SR et al. 
(1998)  suggested  the  role  of  CRH2  receptors  in  the 
anorexic  effect  of  CRH  through  antalarmin  admin-
istration, a CRH1 receptor antagonist (151). Finally, a 
series of  other  studies have demonstrated this rela-
tionship  by  performing  an  adrenalectomy  in  genet-
ically  obese  animals.  Results  indicated  that  an  in-
crease in endogenous CRF in such animals resulted in 
reduced food intake and increased sympathetic activ-
ity (158-161).  
Several studies have found a negative correlation 
between  food  intake  and  sympathetic  activity 
(158,162,163). As a result of sympathetic innervation, 
brown adipose tissue (BAT) has the ability to undergo 
non-shivering thermogenesis, resulting in weight loss 
of CRF-infused rats. Sympathetic stimulation elevates 
norepinephrine,  increases  heart  rate  and  releases 
glucocorticoids  (164-171).  Sympathetic  stimula-
tion-induced-lipolysis is supported by a rise seen in 
the levels of cholesterol, triglycerides and FFA in the 
circulation (158,162,163). More importantly, the sym-
pathetic  mechanism  of  the  BAT  functions  inde-
pendently of other bodily tissues (158,162,163). 
Other studies have looked at CRF in the reverse 
relationship between food intake and energy utiliza-
tion, mediated by the SNS (44). Arase K et al. (1988) 
explored the acute and chronic effects of CRF infusion 
in the third ventricle of rats (149). Acutely, CRF re-
duced  food  intake,  but  significantly  increased  sym-
pathetic activity, while chronically, a prolonged but 
steady loss in weight was noted (149). Arase K et al. 
(1988) demonstrated that food intake and sympathetic 
stimulation were reciprocally-related when exploring 
the diurnal rhythm between both groups of rats (149). 
Moreover, rats under CRF-treatment demonstrated a 
low fat pad weight, suggesting that fat and muscle are 
possible sources of tissue loss under CRH-treatment. 
However, Cullen MJ et al. (2001) put forth that fat pad 
weight was an insensitive measure (44) and carcass fat 
is  what  was  actually  reduced  after  chronic  central 
CRF infusion (172). 
CRF in Conditioned Fear 
An  important  component  of  AN  is  persistent 
fear. This fear is irrational and conditioned to weight 
gain. The model described for fear involves the for-
mation  of  memory  after  an  acute  stressful  event 
(173-175). The CRF released into the HPA-axis as a 
result of stress, further requires an interplay of several 
molecular processes (176) and hippocampal CRF re-
ceptor activation (173) for the formation of memory. 
As depicted in Figure 3, memory formation requires 
the interaction of two core signaling pathways, cyclic 
adenosine  monophosphate  -dependent  protein  ki-
nases (PEK) and mitogen-activated extracellular sig-
nal-regulated  kinases  (Mek-1/2)  (177-179).  El-
liott-Hunt  CR  et  al.  (2002)  demonstrated  that  CRF 
helps  in  the  activation  of  both  PEK  and  Mek-1/2 
through CRF1 and CRF2 receptors (180-182), and in-
creased  expression  of  CRF2  mRNA  was  shown  to 
promote  associative  and  stress-enhanced  learning 
(176).  
Radulovic  et  al.  (1999)  found  that  injecting  a 
nonselective CRF receptor antagonist, astressin, pre-
vented the augmentation of fear conditioning (173). 
However  according  to  Sananbenesi  F  et  al.  (2003), 
administering  a  selective  CRF2  receptor  antagonist, 
ASV-30,  prevented  fear  conditioning  after  an  acute 
stressful event (176).  
Moreover, Ho et al. (2001) further evaluated the 
role  of  CRF2  receptors  in  fear  conditioning  by  ob-
serving  the  shock-induced  freezing  response  (61). 
Rats,  treated  with  antisense  oligonucleotides  for  7 
days, showed a 60-80% reduction in the overall effect 
of CRF2 receptors. Analgesic tests were used to con-
trol for loss of pain sensation. Therefore, inhibition of 
the CRF2 receptors in the lateral septum was shown to 
significantly reduce contextual fear conditioning (61). 
In addition, Hammack et al. (2003) also suggested that 
CRF2  receptors  in  the  dorsal  raphe  were  probably 
involved  in  the  stress-mediated  fear  conditioning 
(183).  
Nevertheless, it is important to consider the in-
volvement  of  the  amygdala  in  the  formation  of 
CRF-induced emotion arousing memories. The baso-
lateral  complex  (BLA)  and  central  nuclei  of  the 
amygdala have projection neurons with densely pop-
ulated CRH receptors (184-186). Roozendaal B et al. Int. J. Med. Sci. 2011, 8 
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(2002) found that injecting a CRF antagonist, α-helical 
CRF,  in  the  BLA  of  the  amygdala  immediately 
post-training  resulted  in  dose-dependent  inhibitory 
avoidance retention impairment (175). Therefore, this 
suggests that the antagonist interfered with memory 
formation at the level of the BLA. In conclusion, the 
hippocampus,  amygdala,  lateral  septum  and  dorsal 
raphe work collectively in the process of CRF-induced 
fear conditioning. Further, this sheds light upon the 
potential  pharmacological  interventions  for  treating 
fear complexes in AN.  
Hypercortisolemia 
Hypercortisolemia  with  elevated  CRH  is  com-
monly seen in protein-caloric depleted anorexic pa-
tients (2). Hypercortisolemia is associated with exces-
sive fear, atherosclerosis, osteoporosis and decreased 
immune function (72). Elevated cortisol has shown to 
suppress  the  mesolimbic-doparminogenic  system 
(172), responsible for the reward-mediated behavior 
(187).  Cortisol  also  regulates  the  negative  feedback 
mechanism for CRH secretion. Possibly, the intense 
fear seen in AN can be explained by the rise in CRH 
and cortisol levels.  
Psychological Perspective 
Heinrichs et al. (1993) studied the mechanism of 
CRF-mediated feeding and  proposed that NPY and 
CRF  work  collectively  to  regulate  feeding  behavior 
(188). CRF and endogenous NPY were found to work 
in  opposite  directions  in  modifying  the  behavioral 
and physiological effects of AN (189-192). Moreover, 
NPY  has  found  to  be  most  potent  when  injected 
nearby to the CRF neurons at the PVNH (193-196) and 
during HPA-axis activation (197-198). NPY has also 
shown to potentiate feeding through a negative glu-
cocorticoid feedback mechanism and by a direct re-
ceptor antagonism at the PVNH (188). High levels of 
NPY and greater mRNA expression in the NPY neu-
rons have been demonstrated in food deprived rats. 
However,  these  levels  return  to  baseline  upon 
re-feeding  (189-201).  Many  behavioral  studies  have 
observed a psychological basis of how NPY invokes 
feeding behavior. It has been thought that NPY helps 
motivate eating. Therefore, dysfunctional NPY with 
CRF function influence the nature of feeding observed 
in AN, resulting in psychological alterations like, mo-
tivation towards dieting, psychosocial influences and 
stress (2).  
Moreover, CRH production takes place at both 
the hypothalamus and the amygdala. CRH from the 
hypothalamus is reactive to the physiological aspects 
of AN, while that from the amygdala is reactive to 
psychological stress (72). Since AN consists of both a 
physiological and psychological component, this im-
plies  that  CRH  from  both  the  hypothalamus  and 
amygdala are responsible for anorexic behavior as a 
function of stress. Further, Kaye WH (1996) found a 
correlation  between  depression  and  CRH  in  those 
individuals  that  were  psychologically  dissatisfied 
with their weight, and not in subjects of constitutional 
thinness  (SOCT)  (2).  In  support,  Pacak  et  al.  (2002) 
also  looked  at  depressed  individuals  with  suicidal 
tendencies and demonstrated high levels of CRH in 
the locus coeruleus, median raphe and caudal dorsal 
raphe by 30%, 39% and 45%, respectively (172).  
OPIOID PEPTIDES 
Neurological Perspective 
Opioids  are  responsible  for  regulating  feeding 
behavior (81). Hubner HF (1993) found that adminis-
tering  naloxone  (opioid  antagonist)  to  anorexics  re-
sulted in weight gain, suggesting that opioids were 
potential  mediators  of  anorexic  behavior  (202).  A 
study by Abbate-Daga G et al. (2007) compared opi-
ate-addicts to anorexic men and found similarities in 
the  following  personality  traits:  anxiety,  fearfulness 
and  antisocial  features  (203).  However,  there  were 
distinct  differences  between  both  groups.  Anorexic 
men  displayed  a  higher  persistence,  but  a  low  re-
ward-dependence,  while  opiate-addicts  were  high 
novelty  seekers  and  scored  better  on 
self-transcendence (203). Therefore, key differences in 
the  pathogenesis  of  opiate-addiction  and  AN  do 
clearly  exist.  Furthermore,  an  atypical  endogenous 
opioid system seems to be present in anorexics, thus 
biologically predisposing them to develop AN (204). 
As discussed earlier, this supports the high heritabil-
ity of AN, and suggests that the psychological com-
ponent of AN is perhaps biologically-determined.  
 Lesem et al. (1991) observed that CSF levels of 
dynorphins were at normal values during all stages of 
AN (2). Moreover, opioids like β-EP are considered 
important in symptom perpetuation and relapses seen 
in AN. However, β-EP levels have shown to normal-
ize after weight gain (202,205-207). Studies have also 
found a normal to reduced β-EP level in the CSF of 
anorexics  (208).  Hubner  HF  (1993)  suggested  that 
β-EP  levels  exhibit  a  biphasic  effect  on  food  and 
weight regulation (202). Therefore, both low and high 
levels of β-EP have shown to inhibit feeding (2,141). 
Kaye WH et al. (1987) further concluded that low lev-
els of β-EP persist, but as patients recover, β-EP levels 
also normalize (206). Moreover, while low levels of 
plasma  β-EP  have  been  demonstrated  in  anorexics 
(84,  209),  Tepper  et  al.  (1992)  found  a  significantly 
elevated level of β-EP in AN (210). In addition, Bram-Int. J. Med. Sci. 2011, 8 
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billa F et al. (1991) have demonstrated elevated levels 
of β-LP in anorexics (209).  
To add to this phenomenon, Brambilla F et al. 
(1991)  studied  the  dynamic  peripheral  secretion  of 
β-EP and β-LP in AN (209). It was observed that both 
peptides were constantly elevated over a 24-hour pe-
riod, particularly during the night (209). This suggests 
the  involvement  of  the  POMC  system.  However,  a 
disassociation in the secretion of β-EP and β-LP was 
noticed,  where  β-EP  was  secreted  only  during  the 
early hours of the night, and β-LP was secreted both 
during the day and at night (209). This implies that 
independent sources and regulatory methods for both 
peptides exist (209). Furthermore, studies have found 
an intermediate layer that exists in the human pitui-
tary  between  the  anterior  and  posterior  lobes.  This 
layer contains β-EP staining cells that have shown to 
increase  during  physiological  and  pathological  con-
ditions.  Therefore,  the  disassociation  between  both 
peptides is possibly due to secretion from an alternate 
focus  (209,211,212).  In  support,  Brambilla  F  et  al. 
(1991)  concluded  that  the  anterior  pituitary  POMC 
hypersecretion was due to starvation (209). However, 
β-EP has no such relation. Also, β-LP, not β-EP, was 
linked to weight loss, suggesting that  β-EP secretes 
from an alternate focus (209). All in all, eating disor-
ders  which  range  from  obesity  to  AN  have  three 
dysfunctional  components  affecting  hunger  and  sa-
tiety:  abnormal  levels  of  peripheral  β-EP  and  β-LP 
secretion, dysfunctional circadian rhythm and POMC 
peptide disassociation (209). 
 Brambilla F et al. (1991) also observed disruption 
in the normal rhythmicity of β-EP and β-LP secretion, 
while cortisol secretion continued to follow a normal 
pattern (209). This further supports the disassociation 
seen  in  the  POMC-derived  peptides,  suggesting  a 
disassociation  of  the  hypothalamic  and  suprahypo-
thalamic function (209). 
Moreover, Glass et al. (2003) experimented with 
rats and provided evidence on the effect of different 
opioids on deprivation-induced feeding (213). When 
δ2-opioid antagonist, naltrindole isothiocyanate, was 
injected  into  the  ventral  tegmentum,  depriva-
tion-induced  feeding  showed  insignificant  changes. 
However, when κ antagonist, norbinaltorphimine was 
injected,  deprivation-induced  feeding  significantly 
declined. Similarly, µ opioids demonstrated the most 
significant decline in food intake among all opioids 
(213). Since there was a profound reduction in food 
intake,  this  implies  that  AN  is  perhaps  due  to  the 
malfunction of the facilitation of reward system me-
diated  by  the  antagonistic  κ  and  µ  opioids  (213). 
Moreover,  the  CSF  of  wasted  anorexics  has  shown 
high  levels  of  those  substrates  that  are  mediated 
through the µ receptors (207). Certain antagonistic δ 
receptors  have  also  shown  a  statistically  significant 
effect  on  reduced  food  intake.  Moreover, 
self-stimulation  plays  a  role  in  regulating  anorexic 
behavior. An opioid antagonist, naltrexone alleviates 
symptoms of AN. This produces an opposite reaction 
where  the  perifornical  lateral  hypothalamus  creates 
an  expression  of  self-stimulation  and  further  pro-
motes the “hunger” response (88).  
Pharmacological Perspective 
Ciccocioppo R et al. (2004) provides insight into 
a potential pharmacological drug with anti-anorexic 
effects  (214).  Researchers  found  that  neuropeptides, 
nociceptin/orphanin  FQ  (N/OFQ)  and  Ro  64-6198 
[synthetic nociceptin (NOP) receptor agonist], exhibit 
anti-anorexic  properties  (214).  N/OFQ,  structurally 
related to dynorphin A, binds to the NOP receptors in 
the brain (215,216). When rats were injected three to 
four micrograms of N/OFQ intracerebroventricularly 
and two and half milligrams/kilogram of Ro 64-6198 
intraperitoneally, they fed at an abnormally high rate 
(214). Moreover, the effects of N/OFQ along the dif-
ferent  sects  of  the  CRF  mechanism  have  been  ex-
plored. Injecting N/OFQ at the VMH (0.5 Ag/site), 
the  PVNH  (0.5  Ag/site),  the  central  nucleus  of  the 
amygdala (0.5 Ag/site), the locus coeruleus and the 
dorsal  raphe  nucleus  (1.0  Ag/rat)  demonstrated  no 
change in anorexic behavior (214). However, injecting 
0.025–0.25 Ag of N/OFQ  in the bed nucleus  of the 
stria terminalis in mice diminished the anorexic be-
havior (217). Gene knockout experiments performed 
on mice also demonstrated a high level of reaction to 
stress  in  the  absence  of  the  N/OFQ  gene  (218). 
Moreover, the medial section  of bed nucleus  of the 
stria  terminalis  has  been  associated  with  the  emo-
tional  aspects  of  stress  (214).  In  conclusion,  future 
drugs should focus on the NOP receptor system with 
drugs  similar  to  N/OFQ  and  Ro  64-6195  for  the 
treatment of AN.  
Psycho-bio-evolutionary perspective 
The mechanism proposed by Yeomans MR et al. 
(2002)  provides  a  psycho-neurochemical  under-
standing of the opioid system in AN (81). According 
to the model, AN initially begins with dieting. This 
leads to a release of opioids and produces a pleasant 
mood. The second part of the model operates inde-
pendently  and  counteractively  from  the  first  where 
the desire to eat inclines, in order to balance the initial 
self-induced  starvation.  Finally,  the  third  step  in-
volves  adapting  to  starvation  by  reducing  energy 
output (81). In AN, the first and final steps dominate, Int. J. Med. Sci. 2011, 8 
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so  that  the  individual  becomes  addicted  to  dieting 
and adapts to starvation (88).  
Moreover, Davis C et al. (1998) studied the act of 
self-starvation, aggravated by physical exercise (219). 
This, itself, is thought to be an addiction to the en-
dogenous opioid system (219). On the Eysenck Per-
sonality  Questionnaire’s  addiction  scale,  anorexics 
seemed to score high, being similar to the scores of 
drug  addicts  and  alcoholics.  Anorexics  also  mani-
fested  high  levels  of  addictiveness  and  OCD  traits 
towards weight loss and exercise. The auto-addiction 
opioid theory hypothesizes that “chronic eating dis-
orders  are  an  addiction  to  the  body's  endogenous 
opioids”  (219).  Moreover,  starvation  and  excessive 
physical activity have also shown to increase levels of 
β-EP, further stimulating dopamine in the mesolimbic 
reward centers (220,221).  
On the other hand, the opioid system involve-
ment in AN has thought to have undergone evolu-
tionary changes. Therefore, this suggests that AN is a 
result  of  opioid-mediated  mechanisms  that  have 
helped animals and humans adapt to short-term food 
restrictions  (81).  This  mechanism  also  helps  reduce 
the psychological effects associated with food depri-
vation.    
GHRELIN 
During the acute stages of AN, ghrelin levels are 
distinctly  elevated  up  to  two-folds  and  return  to 
normal  levels  after  weight  restoration  (95,222-229). 
Several studies (Figure 1) have demonstrated a nega-
tive  correlation  between  BMI  and  ghrelin  levels 
(95,222,229,230). This reflects a state of negative en-
ergy balance. Moreover, fluctuations in the levels of 
ghrelin are not always influenced by food intake in 
AN. This suggests some impairment in the regulation 
of ghrelin (231), perhaps due to chronic adaptation to 
long-standing food restriction (232). 
A study by Tolle V et al. (2003) compared ghrelin 
levels and other nutritional parameters in anorexics 
and SOCT (229). In AN, patients demonstrated a lim-
ited intake of food, BMI <17.5 and reduced body fat, 
coupled with multiple endocrine changes like hyper-
cortisolism (233,234), hypothyroidism (235), amenor-
rhea (236), hypoleptinemia (127,237), hyperghreline-
mia (91) and alteration of the GH-IGF-1 axis with GH 
hypersecretion and low IGF-I (238,239). On the con-
trary, while SOCT and anorexics both displayed par-
allel  BMIs,  SOCT  underwent  normal  menstruation 
and lacked the abnormal feeding behavior. This was 
further supported by a normal triiodothyronine level, 
a  precise  indicator  of  calorie  restriction,  in  SOCT 
(229,240,241). In addition, SOCT exhibited results of 
other  endocrine  factors  (17-β-estradiol,  cortisol,  GH 
and  IGF-1)  similar  to  the  healthy  control  group. 
Therefore, these factors are possible indicators of AN 
(229).  Moreover,  the  normal  circadian  rhythm  in 
ghrelin  secretion  has  been  demonstrated  in  SOCT 
(229),  as  also  earlier  demonstrated  in  healthy  indi-
viduals (94). However, this rhythmicity is absent in 
AN, with a maximal peak occurring only during the 
night (229). Moreover, intermediate levels of ghrelin 
have  been  observed  in  SOCT.  This  signifies  that 
ghrelin partly depends on fat content. This is further 
supported by the negative correlation (Figure 1) seen 
between BMI and ghrelin levels (95,223,229). 
Moreover,  circulating  acyl-ghrelin  is  raised 
during all phases of an oral glucose tolerance test in 
AN (222,230). Further studies have described a much 
higher  level  of  acyl-ghrelin  in  anorexics  than  their 
BMI-matched  control  group  (225-229,242,243).  This 
indicates  that  persistent  hyperghrelinemia  possibly 
impairs  ghrelin  sensitivity  and  contributes  to  the 
pathogenesis of AN (91). This can be compared to the 
leptin resistance observed in obesity where subjects 
are  persistently  hyperleptinemic  (91).  Furthermore, 
persistent  hyperghrelinemia  possibly  impairs  the 
GH/IGF-1 axis, resulting in elevated GH with a par-
adoxical fall in IGF-1 levels (244-247). Moreover, an-
other study in search of a theory behind “ghrelin re-
sistance” discovered the presence of naturally occur-
ring auto-antibodies to ghrelin (248).  
 
 
 
Figure 1: This diagram shows a gradient relationship between both ghrelin levels and body fat mass in a normal, SOCT and 
AN patients.  Int. J. Med. Sci. 2011, 8 
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In  physiological  conditions,  these  au-
to-antibodies  regulate  ghrelin  levels  in  plasma. 
However, Terashi M et al. (2011) found a significant 
drop in the levels of acyl-ghrelin immunoglobulin G, 
immunoglobulin  M  and  immunoglobulin  A  au-
to-antibodies in anorexics, persisting to over a month 
after renutrition (248).  
Furthermore,  many  studies  have  explored  the 
effects of ghrelin treatment in AN. In a study by Hotta 
M  et  al.  (2009),  six  anorexic  patients  were  intrave-
nously  infused  with  three  micrograms/kilogram  of 
ghrelin two times daily for fourteen days (249). As a 
result,  energy  intake  increased  by  12-36%  with  re-
duced  complains  of  epigastric  discomfort  and  con-
stipation in four patients (249). Also, a significant in-
crease in hunger scores, evaluated by the visual ana-
logue  scale,  was  observed.  In  another  study  by 
Broglio F et al. (2004), a bolus injection of intravenous 
ghrelin  (one  microgram/kilogram)  brought  out  a 
feeling of hunger in six of the nine patients studied 
(250). In conclusion, ghrelin demonstrated no adverse 
side  effects  in  the  subjects  (101,249),  but  rather  it 
seemed to bring out beneficial changes. An increase in 
blood glucose levels were observed (251), supporting 
earlier results suggesting that ghrelin prevented death 
by  maintaining  normoglycemia  in  GOAT  -/-  mice 
during periods of starvation (252). 
Miljic  et  al.  (2006)  studied  the  effects  of  pro-
longed ghrelin infusion, using a five hour protocol, on 
appetite, sleep and neuroendocrine responses in ano-
rexics (101). As a result, such infusions were unable to 
bring  forth  normal  GH  and  appetite  responses. 
However, they suggested that a persistent alteration 
in the levels of ghrelin and GH response to ghrelin in 
a  partially-recovered  anorexic  subject,  implied  per-
sistence  of  the  eating  disorder  (101).  Moreover,  in-
creased sleepiness was observed after the fifth hour of 
infusion  (101).  In  addition,  previous  studies  have 
demonstrated  the  role  of  ghrelin  in  maintaining 
slow-wave  sleep  in  humans  (253).  However,  sleep 
curtailment has shown to limit the secretion of both 
ghrelin and GH (254-256). 
LEPTIN 
Leptin exerts its action through binding at two 
different  groups  of  neurons  at  the  ARCH.  The  pe-
ripheral peptide accesses its receptor (ObRb) through 
a modified blood brain barrier (257). Binding to the 
ObRb receptor, the neurons are immediately excited 
and result in secretion of POMC, a protein that further 
disintegrates into α-melanocyte stimulating hormone 
(α-MSH)  (258).  α-MSH,  an  anorexigenic  neuropep-
tide, activates the melanocortin-4 (MC4R) and mela-
nocortin-3 (MC3R) receptors and reduces food intake 
(259,260,261). In addition, secretion of POMC leads to 
cocaine-and  amphetamine-regulated  transcript 
(CART), which further suppresses appetite (262). On 
the contrary, leptin inhibits the AgRP and NPY neu-
rons,  shown  to  express  orexigenic  neuropeptides 
(260).  While  AgRP  has  shown  to  hinder 
α-MSH/MC4R  signaling  (261,263),  NPY  increases 
food  intake  and  decreases  energy  loss  (264,265). 
Moreover,  the  ARCH  accounts  for  only  15-20%  of 
ObRb receptors in the CNS (261,266). Another crucial 
site for leptin action is at the VMH. Two anorexigenic 
neuropeptides,  steroidogenic  factor-1  (SF-1)  and 
brain-derived neurotrophic factor are secreted when 
leptin binds to the VMH (265,267). SF-1 is a transcrip-
tion factor essential for the development of the VMH 
(265,267), while brain-derived neurotrophic factor, a 
neurotrophin,  supports  brain  growth  and  controls 
food consumption (268). 
Furthermore, Tolle V et al. (2003) demonstrated 
significantly  low  levels  of  leptin  over  a  twen-
ty-four-hour  sampling  period  in  anorexics  (229). 
However, these levels returned to baseline upon re-
nutrition  (127,229,237,269-271).  As  demonstrated  in 
Figure  2,  intermediate  levels  of  leptin  are  found  in 
SOCT, falling in between AN and the healthy control 
group (229). 
 
 
Figure 2: This diagram shows a gradient relationship between both leptin levels and body fat mass in a normal, SOCT and 
AN patients. Int. J. Med. Sci. 2011, 8 
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Moreover, body fat mass directly correlates with 
leptin  levels  (272,273).  Even  though  anorexics  and 
SOCT follow parallel BMIs, the body composition of 
the latter group corresponds better with the control. 
In AN, an excessive diminution of body fat mass is 
undoubtedly seen. Since SOCT exhibit a greater net 
body  mass  than  that  of  anorexics,  the  intermediate 
levels  of  leptin  evidently  correspond  better  with 
SOCT (Figure 2) (229). Moreover, a partial recovery in 
weight demonstrates an inverse relation between lep-
tin levels and relapse after a one year follow-up (274). 
In  recent  weight-recovered  anorexics,  leptin  levels 
were found to be greater than of their BMI-matched 
control group. Therefore, this poses difficulties in the 
further  treatment  of  AN  (237,274,275).  Moreover, 
Holtkamp et al. (2003) demonstrated a negative cor-
relation  between  leptin  levels  and  scores  for  motor 
restlessness (276). As a result, pre-clinical and clinical 
studies  have  supported  hypoleptinemia  as  the  key 
factor underlying exaggerated physical activity in AN 
(277).  
SEX DIFFERENCES IN THE CRF, 
OPIOIDS, GHRELIN AND LEPTIN 
Understanding  the  sex  differences  within  the 
CRF and opioid mechanisms  helps stratify their ef-
fects in AN. A study by Rivest S et al. (1989) explores 
the effects of sex differences on energy balance (164). 
When  CRF,  representing  stress/exercise  (278-280), 
was  infused  intraventricularly  over  fourteen  days, 
food intake (protein and fat gain), body weight and 
energy were reduced in male rats. However, no such 
changes  were  seen  in  females  (164).  Moreover,  the 
male and female sex hormones, testosterone and es-
trogen, respectively, are important for mediating CRF 
and sex differences. The estrogen receptor 1 and es-
trogen receptor 2 genes, coding for estrogen α and β 
receptors,  are  located  with  CRF  and  co-regulate  its 
expression  (281,282).  In  addition,  Versini  A  et  al. 
(2010)  associated  estrogen  receptor  1  gene  with  the 
RAN  subtype  (283).  Moreover,  same-sex  and  oppo-
site-sex twin studies further support the greater inci-
dence of AN in females (9,15-20). This is probably due 
to the intrauterine exposure of sex hormones. Also, 
while estrogen has shown to regulate feeding behav-
ior in females, testosterone has shown minimal effect 
in males (153).  
Administering  a  selective  estrogen  α-receptor 
agonist to ovariectomized rats led to decreased food 
intake  and  body  weight  (284).  These  agonists  also 
produced varying effects of “social learning of food 
preference” (285). Furthermore, CRF demonstrates an 
inhibitory  role  on  gonadotropin-releasing  hormone, 
and  subsequently  gonadotropin  in  both  sexes.  This 
action is regulated through the opioid-mediated in-
hibiting action (286-288). Also, CRF reduces estrogen 
and limits its effect on anorexic behavior in females 
(289-292),  suggesting  that  low  estrogen  encourages 
energy intake (289,293,294). Other studies have sug-
gested  that  both  estrogen  and  progesterone  inhibit 
feeding under basal (295,296) and inflammatory con-
ditions (297). Estrogen has shown to mediate inhibi-
tory signals for gastric distension and cholecystokinin 
during  digestion  (298).  Moreover,  Miller  KK  et  al. 
(2005)  suggests  that  testosterone  attenuates  the 
symptoms  of  AN  (299),  but  other  studies  have 
demonstrated no effect between low testosterone level 
and food intake (153,300). In support, Leal et al. (1997) 
found  no  relationship  between  food  restriction  and 
diurnal variation of plasma testosterone and andros-
tenedione level in male rats (301). Therefore, the ad-
renal secretion of corticosterone less likely mediates 
the  diurnal  change  seen  in  the  male  sex  hormones. 
Moreover, many studies have shown sex differences 
in  the  sympathetically-driven  BAT  thermogenesis 
(301). They found that CRF infusion resulted in high 
levels of BAT protein in males, but no such effect was 
seen in females (301).  
Sex  differences  have  shown  to  influence  the 
functioning  of  the  opioid  system.  This  provides  in-
sight into why AN is ten to twenty times more prev-
alent in females (1). Preliminary research on animals 
demonstrated that µ opioids are more potent in fe-
males and κ opioids are more potent in males. How-
ever, δ opioids demonstrated similar effects in both 
sexes (302). Therefore, further research is necessary to 
understand the sex differences in the effects of µ, κ 
and δ opioids. Moreover, a pharmacodynamic basis in 
the  sex  difference  of  the  opioid  mechanism  exists. 
Pharmacodynamic  differences  include  the  distribu-
tion and density of opioid receptors at different areas 
of the brain. Research suggests that the male and fe-
male hypothalamus exhibit a significant difference in 
the density of opioid receptors. Accordingly, studies 
have found higher densities of µ opioids in the male 
hypothalamus. Gonadal hormones like estrogen have 
also shown to mediate the levels of opioid and opioid 
receptor concentration (302).  
Studies  have  shown  that  females  who  suffer 
through chronic illnesses experience early satiety, and 
present with a high anorexic response related to leptin 
and tumour necrosis factor– α (303,304). Gayle DA et 
al. (2006) supported the differential feeding regulation 
between male and female rats (305). The sex differ-
ences in the levels of ghrelin and leptin were studied 
through  administering  an  orexigenic  (calorie  re-
striction) and anorexigenic (inflammatory) stimuli. In 
both instances, females showed a more positive and Int. J. Med. Sci. 2011, 8 
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stronger  response  than  their  male  counterparts.  In 
females, the orexigenic stimuli led to increased feed-
ing  and  high  levels  of  plasma  ghrelin,  whereas  the 
anorexigenic stimuli only led to a high plasma leptin 
level. In the inflammatory phenomena, the sex inter-
actions of cytokines, interleukin-1-β and tumour ne-
crosis factor-α with leptin and ghrelin further describe 
the  differential  feeding  in  males  and  females  (305). 
Accordingly, cytokines have shown to increase leptin 
(306,307) and decrease ghrelin levels (308). Moreover, 
basal  leptin  levels  are  generally  greater  in  females. 
Therefore, since high leptin levels are thought to be 
anorexigenic,  this  provides  insight  into  why  female 
prevalence is greater in AN. 
DISCUSSION 
The  CRF,  opioids,  ghrelin  and  leptin  mecha-
nisms operate collectively to demonstrate the under-
lying  physiological  and  psychological  changes  in 
feeding  behavior  of  anorexics  (Figure  3).  Moreover, 
these mechanisms have shown to overlap at the HPA 
axis.  These  interactions  are  complex  and  provide  a 
holistic account for both the physiological and psy-
chological manifestations of AN. 
Firstly, the CRF mechanism plays a central role 
in AN. Literature has suggested that the dysfunction 
of the CRF mechanism plays a considerable role in the 
pathogenesis of AN (141). Its actions are broadly dis-
tributed within the CNS and PNS, accounting for the 
various visceral and behavioral manifestations of AN 
(40). The hyperactivity of the HPA axis, resulting in 
elevated CRF levels in the CSF (39), has been impli-
cated in the pathogenesis of AN (309). The hyperac-
tivity  of  the  HPA  axis  results  in  a  negative  energy 
balance,  disturbances  in  sexual  function,  cardiovas-
cular  changes  and  mood  disturbances  (147-149). 
Moreover, CRF1 and CRF2 receptors have shown to 
mediate the actions of CRF (42-44). In specific, CRF2 
receptors have shown to mediate CRF actions of en-
ergy intake, independent of the HPA axis (155). The 
HPA  axis-independent  pathway  functions  through 
the  CRF2  receptors,  mediated  by  UCN  (156,157). 
Therefore, CRF regulates energy balance through two 
independent pathways.  
 
 
Figure 3: Interaction of CRF, opioids, ghrelin and leptin mechanisms in AN. This diagram represents the key pathways 
involved in the spectrum of physiological and psychological symptoms of AN. Int. J. Med. Sci. 2011, 8 
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However,  it  is  important  to  note  the  effect  of 
each  pathway  on  energy  balance.  The  HPA  ax-
is-dependent pathway acts at the central and periph-
eral level, producing a negative energy balance with 
activation of the SNS (32,33,73). While, the HPA ax-
is-independent pathway affects energy intake, it lacks 
peripheral  activation  (44).  The  implications  of  this 
dual relationship are two-fold. Both pathways have 
shown to regulate energy balance through CRF and 
UCN.  
However, in support of Baranowska B (1990), the 
CRF mechanism better accounts for the negative en-
ergy balance seen in AN (141). Therapeutically, both 
pathways  need  to  be  fully  considered,  overlooking 
either one could result in inadequate treatment of AN.  
Irrational  and  persistent  fear  is  an  important 
component of AN (1). The CRF mechanism plays a 
central role in forming a fear response (173). There are 
two HPA-axis related pathways, the independent and 
dependent  pathways  that  have  shown  to  regulate 
fear. Mediation of fear and memory formation occurs 
through an acute stress stimulus (173-175). Moreover, 
the hippocampus (173), amygdala (175), dorsal raphe 
(183)  and  lateral  septum  (61),  work  collectively  to 
produce the fear response. The hippocampus helps in 
the formation of memory, as well as generates a fear 
response  following  an  acute  stress  stimulus.  At  the 
hippocampus, CRF mediates its actions through both 
the CRF1 and CRF2 receptors (180-182). In addition to 
both  the  psychological  (72)  and  physiological  com-
ponents of the fear response, the amygdala is respon-
sible for arousal, fear and rage reactions through ac-
tivation of the SNS (310). Therefore, fear conditioning 
is not fully independent of the HPA axis. The activa-
tion  of  the  SNS  indicates  partial  HPA-axis  involve-
ment. The effects of amygdala are perhaps mediated 
through the CRF1 receptors, since the CRF2 receptors 
have shown to be independent of the HPA axis. The 
functions  of  the  dorsal  raphe  (183)  and  the  lateral 
septum  (61)  are  mediated  by  the  CRF2  receptors. 
Moreover, the short-term  fear response is regulated 
through the CRF1 receptors while the long-term fear 
response  is  regulated  through  the  CRF2  receptors 
(176). Both receptors have shown to activate the initial 
signaling pathways (177-179), but only the CRF2 re-
ceptors promote associative and stress-related learn-
ing (176,180-182). Moreover, the hippocampus is in-
volved  in  both  short-term  and  long-term  effects  of 
fear conditioning, through the action of CRF on both 
receptors, in the hippocampus. In addition, the hip-
pocampus  has  shown  to  consolidate  short-term 
memories  into  long-term  memories  (311).  CRF  also 
regulates  short-term  and  working  memory,  seen  in 
fear conditioning, through the CRF1 receptor. There-
fore,  long-term  changes  in  memory  are  mediated 
through  UCN,  being  the  predominant  agonist  to 
CRF2 receptors. All in all, the hippocampus integrates 
the actions of both the CRF1 and CRF2 receptors to 
form durable memories. The interaction of the dorsal 
raphe and the lateral septum, through the CRF2 re-
ceptors, suggests their involvement in the long-term 
learning process of AN. 
Moreover,  cortisol  represents  another 
CRF-mediated pathway involved in the fear response. 
This pathway is HPA axis-dependent. Claes SJ (2004) 
suggests that hypercortisolemia is linked with exces-
sive fear (72). However, it remains unclear if the fear 
induced by cortisol is qualitatively representative of 
the fear seen in AN. Based on the scarce evidence in 
support of cortisol involvement, it is expected that the 
HPA  axis-independent  pathway  chiefly  modulates 
fear in AN. 
The second component of the model is the opioid 
system (84). We must note the overlap of the opioids 
and CRF mechanism at the HPA axis, particularly at 
the PVNH. Opioid peptides regulate CRF through the 
NA system (312,313). When clonidine stimulates the 
NA system, a blunting of the β-EP and β-LP secretion 
is observed (209). This suggests sub-sensitivity at the 
postsynaptic NA receptor level (209).  
The  locus  coeruleus  is  involved  in  the  sympa-
thetic stimulation mechanism through the release of 
NA  during  stress  (314).  The  locus  coeruleus,  along 
with  the  other  bodily  systems,  help  regulate  stress 
(40), and mediate CRF through the action of opioids. 
Interestingly, starvation inhibits the NA stimulation 
of  CRF,  leading  to  a  depressed  locus  coeruleus 
(312,313).  However,  since  stress  is  a  component  of 
AN, the locus coeruleus is probably activated. There-
fore, the possibilities are two-fold. Firstly, the effect of 
the locus coeruleus could be biphasic, and secondly, 
the  discharge  of  NA  could  be  from  alternate  foci. 
Since starvation reduces the secretion of ACTH and 
cortisol through the NA pathway (312,313), and hy-
percortisolemia has thought to be associated with AN 
(2),  an  alternate  source  of  cortisol  secretion  is  ex-
pected.  Therefore,  taking  into  account  the  biphasic 
effect of the locus coeruleus, therapeutic intervention 
in AN should be cautiously performed.  
Hypercortisolemia  has  shown  to  suppress  the 
mesolimbic doparminogenic system (172), suggesting 
the involvement of antagonistic opioids in AN. This 
may have an effect on hypercortisolemia and mediate 
the  reward-mediated  and  anorexic  behavior.  There-
fore, high levels of cortisol are probably a result of 
dysfunctional opioid peptides (141). Moreover, opioid 
agonists to the µ receptors may help alleviate symp-
toms of AN related to hypercortisolemia. In addition, Int. J. Med. Sci. 2011, 8 
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N/OFQ and Ro 64-6198 have also demonstrated an-
ti-anorexic effects (214).  
Moreover, it is essential that we also consider the 
reverse  and  more  direct  relationship  between  CRF 
and opioid peptides. The dysfunctional CRF mecha-
nism seems to directly affect the opioid system. First-
ly, this direct link could explain the inhibitory effect of 
CRF  on  gonadotropin-releasing  hormone  through 
opioid-mediated inhibiting action (286-288). This in-
teraction  provides  insight  into  the  overlap  seen  be-
tween CRF and opioid peptides. Moreover, Brambilla 
F et al. (1991) observed a normal secretion of β-EP and 
β-LP  after  CRH  stimulation  in  anorexics  (209).  The 
reasoning is two-fold. Firstly, this suggests a loss in 
rhythmicity of opioid secretion due to dysfunctional 
opioids  at  the  level  of  hypothala-
mus/suprahypothalamus.  Secondly,  this  provides 
insight into the location of the overlap between CRF 
and opioid peptides.  
The regulation of ghrelin adds another dimen-
sion to the pathogenesis of AN. It is important to dif-
ferentiate  anorexics  from  SOCT.  Germain  N  et  al. 
(2007)  concluded  that  SOCT  were  characterized  by 
high  peptide  YY  concentration,  low  ghrelin  and 
low-to-normal  levels  of  glucagon-like-peptide-1  and 
leptin,  while  anorexics  demonstrated  a  low  peptide 
YY, high ghrelin and low leptin concentration, sug-
gesting an orexigenic adaptive mechanism of appetite 
regulation in response to low food intake in AN (243). 
Regardless of an orexigenic profile, anorexics refuse 
any sort of food intake. This implies that “psycholog-
ical  determinism”  plays  an  important  role  (243). 
Moreover,  the  psycho-behavioral  aspects  of  opioids 
emphasize  the  addictiveness  of  anorexic  behavior. 
Therefore, both addictiveness and the element of fear 
should be considered in the suppression of the normal 
physiological  response.  Current  evidence  suggests 
that  the  physiological  component  outweighs  the 
psychological component. However, according to the 
integration  model  proposed  by  this  paper,  the  psy-
chological  component  seems  to  be  an  indispensible 
component of AN.  
According to Germain N et al. (2007), SOCT ex-
hibit an equilibrated energy metabolism, while ano-
rexics  demonstrate  a  negative  energy  balance  (243). 
While  anorexics  have  a  constant  fear  of  gaining 
weight,  SOCT  put  in  all  efforts  towards  gaining 
weight,  and  often  overfeed  with  the  same  intent 
(243,315).  Therefore,  this  suggests  that  low  body 
weight is not an effective measure of AN. However, 
measures like body fat content and other nutritional 
parameters (discussed earlier), may be useful in dif-
ferentiating  the  two  entities.  Moreover,  CRF  and 
ghrelin also overlap at the hypothalamus. The high 
ghrelin levels result in high ACTH levels, and subse-
quently, hypercortisolemia (233,234). This suggests an 
additional pathway for fear conditioning. Moreover, 
the element of fear and its neurophysiology in AN can 
be understood by three distinct pathways: CRF, cor-
tisol and ghrelin. 
Ghrelin  dysfunction  provides  an  alternative 
mechanism  in  which  low  estrogen  levels  result  in 
musculoskeletal  disturbances  in  AN.  Ghrelin  dis-
turbances  are  also  mediated  through  the  HPA-axis. 
High levels of GH and low levels of IGF-1 result in a 
state of catabolism, which helps maintain the leanness 
of AN (108-110).  
Researchers have identified the role of leptin in 
dysfunctional feeding behavior. Leptin overlaps with 
CRF  at  the  hypothalamus  through  NPY  (260).  Both 
leptin and opioids are involved in the secretion of the 
POMC  peptide,  resulting  in  the  release  of  α-MSH, 
CART and β-LP (84,258,262). Leptin regulates energy 
balance through α-MSH and CART, (258,262) while 
opioids utilize β-LP (84). 
Moreover, evidence shows that ghrelin and lep-
tin function in opposite directions. Ghrelin is orexi-
genic  and  adipogenic  in  action  (93,111-113,115,316), 
while leptin is anorexigenic and supports adipolysis 
(317,318).  These  effects  are  due  to  the  action  of 
NPY/AgRP  on  ghrelin  and  leptin  receptors  in  the 
hypothalamus  (319,320).  Ghrelin  activates  the 
NPY/AgRP neurons (114,316), whereas leptin inhibits 
them  (126,321).  Consequently,  the  negative  energy 
balance  seen  in  AN,  reduces  leptin  levels;  while  a 
positive energy balance seen in obesity, increases lep-
tin levels and decreases plasma ghrelin levels (322). 
Nonetheless,  “If  ghrelin  behaves  like  an  orexigenic 
factor,  the  increase  in  endogenous  ghrelin  levels  in 
AN  could  be  considered  an  adaptive  mechanism, 
promoting  energy  intake  and  increasing  body  fat 
stores in response to a deficit in energy balance” (229). 
Therefore, endogenous ghrelin levels in AN could be 
used as a prognostic marker, differentiating a positive 
outcome from a poor one. In addition to its prognostic 
value, various studies have demonstrated the thera-
peutic  use  of  ghrelin  in  anorexics  (101,249-252).  Fi-
nally, future studies should further evaluate the effi-
cacy of ghrelin in AN.  
Differential  action  of  sex  hormones  gives  rea-
soning  to  AN  being  more  prevalent  in  females.  In 
SOCT, physiological gonadal activity is intact, but in 
anorexics, this activity is absent. The high ghrelin and 
low  leptin  levels  with  abnormal  CRH  activity  has 
shown to suppress the reproductive system (323-325). 
Moreover,  studies  have  implicated  estrogen  in  the 
regulation  of  energy  intake  and  “social  learning  of 
food preference” (285). Also, estrogen has shown to Int. J. Med. Sci. 2011, 8 
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mediate the opioid system and its receptor concentra-
tion through the reverse pathway (302). Perhaps, es-
trogen controls µ receptors and their sex distribution. 
Females have shown to have a greater concentration 
of µ receptors in the CNS than their male counterparts 
(302).  Therefore,  µ  receptors  contribute  to  anorexic 
behavior as well as to increased female prevalence in 
AN.  
Since  µ  receptors  are  involved  in  re-
ward-mediated  behavior  (88),  it  is  important  to  ex-
plore the addictiveness and OCD traits of AN. Davis 
C et al. (1998) provides insight into the understanding 
of  the  addictive  component  through  the  “au-
to-addiction  opioids  theory”  (219).  Moreover,  re-
search  has  demonstrated  associated  OCD  traits  in 
individuals suffering from AN (219). Therefore, sex 
hormones  like  estrogen,  which  mediate  the  opioid 
system  are  associated  with  the  addictive  and  OCD 
traits of AN. As a result, the addictiveness and com-
pulsiveness  are  probably  sex-determined  since  opi-
oids  favor  AN  in  females.  Moreover,  males  may 
demonstrate the physiological changes of AN similar 
to females. However, the addictive and OCD attrib-
utes of opioid function are perhaps inactive in males 
due to differential sex distribution of µ receptors. The 
implications of this are two-fold. Firstly, AN cannot 
be  disassociated  from  its  psychological  component. 
Secondly, the opioid system is a vital component that 
should be targeted in the treatment of AN. Therefore, 
males may only manifest the physiological aspects of 
feeding  and  never  overtly  present  as  AN.  This  is 
perhaps due to the masking effect of the regulatory 
mechanisms present in males. In females, the active 
psychological component of AN takes the upper hand 
and prevents the physiological correction from taking 
place, making the disorder explicit. This notion can be 
further supported by the resistance observed in the 
regulation of ghrelin (231). A similar resistance is also 
seen  with  leptin  levels,  which  poses  difficulties  in 
recovering from AN (91).  
Moreover, female dominance in AN can be ex-
plained  through  the  leptin  mechanism.  In  general, 
females demonstrate a higher baseline level of leptin 
than in males. Since leptin is anorexigenic and sup-
ports adipolysis (317,318), this explains the selective 
sex-dominance in AN.  
In sum, it is important to highlight the cause and 
effect relationship among the different mechanisms of 
AN. Integrating the various dimensions seen in Fig-
ure 3, this would aid clinicians in the management of 
anorexic patients. Studies have linked HPA-axis acti-
vation  with  starvation  (142-145).  This  association 
could be an effect of starvation, where starvation ac-
tivates  the  HPA-axis  and  regulates  various  mecha-
nisms. Brambilla F et al. (1991) further links POMC 
hypersecretion  with  starvation  (209).  Since  POMC 
regulates both leptin and opioids, their involvement 
in starvation is inevitable. Again, this hypersecretion 
is an effect of starvation. According to the Yeomans MR et 
al. (2002) model, initial starvation in AN leads to a re-
lease of opioid peptides (81). This induces a pleasant 
mood, creates an addiction towards dieting and later 
results  in  chronic  adaptation  to  starvation  (81). 
Moreover, opiate-addicts and AN patients have key 
differences  in  their  presentations,  this  further  rein-
forces that opioids are not causally implicated in AN. 
Also, there seems to be an overlap with the physical 
attributes  between  both  groups  (203).  Most  im-
portantly, both groups are physically anorexic; how-
ever, the personality attributes of each group differ 
(203). This supports the atypical functioning of opi-
oids  giving  sufferers  a  unique  spectrum  of  clinical 
manifestations in AN (204).  
On the other hand, leptin directly correlates with 
adiposity  (127).  Devlin  MJ  (2011)  discusses  the  key 
role of leptin in regulating bone marrow fat deposi-
tion during starvation (22). Studies have found high 
amounts of marrow fat in ob/ob mice lacking leptin 
and db/db mice lacking leptin receptors, irrespective 
of obesity (22). However, leptin treatment in ob/ob 
mice was shown to reduce bone marrow fat (326-328). 
Lower  leptin  levels  lead  to  a  persistence  of  bone 
marrow fat, because it promotes autophagy by inhib-
iting the mTOR protein (329,330). The mTOR protein 
has  shown  to  inhibit  autophagy  and  promote  lipo-
genesis  (329,330).  Furthermore,  bone  marrow  fat  is 
resistant to lipolysis until depletion of other fat stores 
occur  (22).  Syed  et  al.  (2008)  have  also  found  high 
levels of bone marrow fat in post-menopausal wom-
en, suggesting that low estrogen levels are associated 
with high bone marrow fat (331). In conclusion, these 
experiments highlight the mechanism through which 
starvation triggers bone marrow fat deposition (22).  
On the contrary, mice experiments have demon-
strated a deficiency of liver IGF-1 with high levels of 
GH associated to low levels of bone marrow fat (332). 
This pattern is similar to the ghrelin level paradigm 
seen  in  AN.  The  implications  of  these  findings  are 
several-fold. Firstly, leptin and estrogen mechanisms 
of AN function independent of one another. Secondly, 
since  bone  marrow  fat  is  protective  and  increases 
survival  rate  during  starvation  (22),  AN  mediated 
through  leptin  and  estrogen  seem  to  be  protective, 
whereas  AN  mediated  through  ghrelin  has  detri-
mental outcomes (Figure 4). Thirdly, since all mecha-
nisms seem to interact with one another, only certain 
factors help favor a single mechanism, either the lep-
tin  and  estrogen  mechanism  or  the  ghrelin  mecha-Int. J. Med. Sci. 2011, 8 
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nism,  to  take  precedence.  Therefore,  future  studies 
should consider exploring the causes of preference in 
either pathway. Thus, these three mechanisms seem 
to predict the survival rate for AN. Patients with low 
levels  of  leptin  and  estrogen  will  perhaps  survive 
longer than those with high ghrelin levels. This also 
sheds light upon males possibly having a better sur-
vival outcome over females in AN.  
 
 
 
Figure  4: This diagram portrays the three survival pre-
dictors  and  their  relationship  with  bone  marrow  fat  in 
starvation. 
 
A Comment on Future Direction 
This paper reviewed the recent and historic evi-
dence of various neurological mechanisms involved 
in  the  pathogenesis  of  AN.  Most  of  the  evidence 
gathered came from experiments performed on mice. 
Experiments  on  mice  help  standardize  tests  and 
eliminate the element of false information. However, 
mice can only be used in understanding the biological 
aspect of AN, since the psychosocial perspective can 
only  be  assessed  on  human  subjects.  However,  ob-
taining an accurate and truthful history is a challenge 
encountered  with  human  subjects.  Moreover,  this 
paper highlights the intricate relation of the psycho-
logical component of AN. Previous experiments have 
strictly examined the physiological component of AN, 
like energy balance. Thus, it would be highly inap-
propriate for us to assume that experiments can in-
duce  AN  in  mice.  Also,  most  studies  have  isolated 
single  mechanisms  and  have  analyzed  their  effects. 
Therefore, it is recommended that future studies ex-
plore the interrelation of various mechanisms in AN. 
Ideally, a cohort study on both prepubertal males and 
females, showing high levels of CRF, should be per-
formed with observations made at regular intervals to 
determine the development of AN. This would elim-
inate the need for extrapolating data from mice onto 
humans.  Finally,  future  studies  should  explore  the 
interactions  between  these  mechanisms  in  post-AN 
patients.  
It  is  important  to  understand  that  starvation 
does  not  necessarily  imply  AN.  If  two  individuals 
suffering from starvation are compared, the question 
arises, are both individuals equally likely to develop 
AN?  In  underdeveloped  countries,  where  young 
children suffer from starvation due to a lack of food, it 
is important to consider the likelihood of these chil-
dren developing AN later in life. As a matter of fact, 
forced  starvation  will  rarely  develop  into  AN.  This 
suggests  that  voluntary  and  involuntary  starvation 
are distinct entities having unique mechanisms. Tra-
ditionally, AN has predominantly affected the west-
ern hemisphere. Therefore, it is essential that we in-
quire whether those that suffer from AN are predis-
posed  to  it.  Moreover,  what  causes  starvation  to 
evolve into AN needs to be addressed in future stud-
ies. It is quite evident that the thin body image por-
trayed  through  the  media  has  an  important  role  in 
AN. The weight loss industries along with the media 
are very affluent industries, and constantly promote 
the glorification of being thin. About 47% of girls en-
rolled between the fifth and the twelfth grades have 
shown the desire to lose weight as a result of maga-
zine  photos  (333),  while  another  69%  of  girls  have 
agreed that magazines have influenced their image of 
the ideal body shape (333). Since, young adolescents 
are constantly being exposed to media, it is vital to 
explore the psychological and biological components 
predisposing an individual to develop AN. Moreover, 
cultural effects seem to intensify the desire to be thin. 
The  western  culture  has  been  a  forerunner  in  pro-
moting  the  thin  body  image.  However,  with  the 
western  influence  percolating,  there  seems  to  be  a 
recent increase of AN in the eastern hemisphere. It is 
also  worth  mentioning  that  many  religious  groups 
promote the importance of being healthy by staying 
thin. In conclusion, the adolescents of today are being 
constantly overwhelmed with the perception of being 
thin, ultimately, forcing an individual to incorporate 
this into their self-concept.  
Understanding these  mechanisms  is crucial to-
wards  developing  newer  innovative  techniques  for 
the management of AN. Research has predominantly 
looked at the CRF and opioid mechanisms separately, Int. J. Med. Sci. 2011, 8 
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and have developed drugs that function individually. 
Therefore,  future  pharmacological  research  should 
integrate knowledge from both systems, and find a 
common functionality for drugs. This will result in a 
drug collectively involving both systems and treating 
a larger array of symptoms. Pharmacological research 
should  further  consider  the  involvement  of  ghrelin 
and leptin. Moreover, this paper delineates the vari-
ous pathways in the manifestation of key symptoms 
in AN. It is imperative to pharmacologically target all 
identified  pathways  to  alleviate  these  symptoms. 
Since all four mechanisms overlap at the HPA-axis, 
targeting the HPA-axis, pharmacologically, is benefi-
cial. However, it must be noted that drugs affecting 
that area would present  with a plethora of adverse 
side  effects.  Therefore,  drugs  targeting  the 
HPA-independent  pathways  should  be  developed. 
Although, being specific in action, this would ensure a 
narrow spectrum of adverse effects. Moreover, since 
adolescents are greatly affected, various different be-
havioral techniques should be attempted. Apart from 
the usual, newer therapies such as provocative ther-
apy, including laughter therapy has been used in the 
treatment of AN (334). In a recent study on the bene-
ficial effects of laughter, moderate levels of laughter 
were shown to promote health, while low and high 
levels demonstrated no effect (335).  
Lastly, to better understand the sex differences in 
AN, future studies should explore AN in those males 
showing excessive female characteristics. This would 
help  understand  the  role  of  sex  hormones  in  AN. 
Moreover, survival in both sexes should be explored 
by inducing the various pathways and observing the 
differences in survival time.  
Finally,  since  many  decades  AN  has  been  a 
feeding  epidemic  in  both  adolescents  and  adult  fe-
males  worldwide.  However,  it  is  slowly  emerging 
into  the  developing  countries.  AN  continues  to  re-
quire  more  investigations  and  academic  inquires  in 
order to achieve a more comprehensive understand-
ing. Therefore, it is imperative that future studies in-
vestigate  additional  neural  mechanisms  that  would 
account for more of the yet unknown in the field of 
AN. 
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